An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway

Persistent activation of signal transducer and activator of transcription 3 (STAT3) is associated with the progression of a range of tumors. In this report, we present the anticancer activity of 2-(1-(4-(2-cyanophenyl)1-benzyl1H-indol-3-yl)-5- (4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5)undecane (CIMO)...

Full description

Bibliographic Details
Main Authors: Sulaiman, N., Mohan, C., Basappa, B., Pandey, V., Rangappa, S., Bharathkumar, H., Kumar, Alan Prem, Lobie, P., Rangappa, K.
Format: Journal Article
Published: Spandidos Publications 2016
Online Access:http://hdl.handle.net/20.500.11937/51573
_version_ 1848758731602395136
author Sulaiman, N.
Mohan, C.
Basappa, B.
Pandey, V.
Rangappa, S.
Bharathkumar, H.
Kumar, Alan Prem
Lobie, P.
Rangappa, K.
author_facet Sulaiman, N.
Mohan, C.
Basappa, B.
Pandey, V.
Rangappa, S.
Bharathkumar, H.
Kumar, Alan Prem
Lobie, P.
Rangappa, K.
author_sort Sulaiman, N.
building Curtin Institutional Repository
collection Online Access
description Persistent activation of signal transducer and activator of transcription 3 (STAT3) is associated with the progression of a range of tumors. In this report, we present the anticancer activity of 2-(1-(4-(2-cyanophenyl)1-benzyl1H-indol-3-yl)-5- (4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5)undecane (CIMO) against breast cancer cells. We observed that CIMO suppresses the proliferation of both estrogen receptor-negative (ER-) (BT-549, MDA-MB231) and estrogen receptor-positive (ER+) (MCF-7, and BT-474) breast cancer (BC) cells with IC50 of 3.05, 3.41, 4.12 and 4.19 M, respectively, and without significantly affecting the viability of normal cells. CIMO was observed to mediate its anti-proliferative effect in ER- BC cells by inhibiting the phosphorylation of JAK2 and STAT3 proteins. Quantitative PCR analysis demonstrated that CIMO decreases the relative mRNA expression of genes that are involved in cell cycle progression (CCND1) and cell survival (BCL2, BCL-xL, BAD, CASP 3/7/9, and TP53). In addition CIMO was observed to arrest BC cells at G0/G1 phase and of the cell cycle. Furthermore, CIMO suppressed BC cell migration and invasion with concordant regulation of genes involved in epithelial to mesechymal transition (CDH1, CDH2, OCLN and VIM). Thus, we report the utility of a synthetic azaspirane which targets the JAK-STAT pathway in ER- BC.
first_indexed 2025-11-14T09:48:39Z
format Journal Article
id curtin-20.500.11937-51573
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:48:39Z
publishDate 2016
publisher Spandidos Publications
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-515732017-09-13T21:24:57Z An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway Sulaiman, N. Mohan, C. Basappa, B. Pandey, V. Rangappa, S. Bharathkumar, H. Kumar, Alan Prem Lobie, P. Rangappa, K. Persistent activation of signal transducer and activator of transcription 3 (STAT3) is associated with the progression of a range of tumors. In this report, we present the anticancer activity of 2-(1-(4-(2-cyanophenyl)1-benzyl1H-indol-3-yl)-5- (4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5)undecane (CIMO) against breast cancer cells. We observed that CIMO suppresses the proliferation of both estrogen receptor-negative (ER-) (BT-549, MDA-MB231) and estrogen receptor-positive (ER+) (MCF-7, and BT-474) breast cancer (BC) cells with IC50 of 3.05, 3.41, 4.12 and 4.19 M, respectively, and without significantly affecting the viability of normal cells. CIMO was observed to mediate its anti-proliferative effect in ER- BC cells by inhibiting the phosphorylation of JAK2 and STAT3 proteins. Quantitative PCR analysis demonstrated that CIMO decreases the relative mRNA expression of genes that are involved in cell cycle progression (CCND1) and cell survival (BCL2, BCL-xL, BAD, CASP 3/7/9, and TP53). In addition CIMO was observed to arrest BC cells at G0/G1 phase and of the cell cycle. Furthermore, CIMO suppressed BC cell migration and invasion with concordant regulation of genes involved in epithelial to mesechymal transition (CDH1, CDH2, OCLN and VIM). Thus, we report the utility of a synthetic azaspirane which targets the JAK-STAT pathway in ER- BC. 2016 Journal Article http://hdl.handle.net/20.500.11937/51573 10.3892/ijo.2016.3615 Spandidos Publications restricted
spellingShingle Sulaiman, N.
Mohan, C.
Basappa, B.
Pandey, V.
Rangappa, S.
Bharathkumar, H.
Kumar, Alan Prem
Lobie, P.
Rangappa, K.
An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title_full An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title_fullStr An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title_full_unstemmed An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title_short An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway
title_sort azaspirane derivative suppresses growth and induces apoptosis of er-positive and er-negative breast cancer cells through the modulation of jak2/stat3 signaling pathway
url http://hdl.handle.net/20.500.11937/51573